Wealth Enhancement Advisory Services LLC Trims Position in Zoetis Inc. $ZTS

Wealth Enhancement Advisory Services LLC lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 33.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,590 shares of the company’s stock after selling 35,578 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Zoetis were worth $9,260,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in Zoetis in the 2nd quarter valued at about $809,491,000. Diamond Hill Capital Management Inc. acquired a new stake in shares of Zoetis in the third quarter worth approximately $394,010,000. Nordea Investment Management AB grew its holdings in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in Zoetis by 83.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock valued at $394,746,000 after purchasing an additional 1,227,085 shares during the period. Finally, Corient Private Wealth LLC increased its position in Zoetis by 85.9% during the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after purchasing an additional 1,191,840 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $113.48 on Friday. The business’s 50-day simple moving average is $123.39 and its 200 day simple moving average is $129.31. The company has a market cap of $47.90 billion, a P/E ratio of 18.85, a PEG ratio of 1.78 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a one year low of $113.29 and a one year high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter last year, the firm posted $1.40 earnings per share. The business’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.9%. Zoetis’s payout ratio is 35.22%.

Analysts Set New Price Targets

A number of brokerages have weighed in on ZTS. HSBC set a $140.00 price target on shares of Zoetis in a report on Wednesday, December 10th. Piper Sandler restated a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Weiss Ratings raised Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, March 12th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, UBS Group set a $136.00 price target on Zoetis in a research note on Thursday, January 29th. Six analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.